Clinical Focus

Previous Articles     Next Articles

Lenalidomide in  treatment of relapsed/refractory nonHodgkin's Bcell lymphoma


  1. 1.Department of Hematology,  Huai'an First People's Hospital,  Nanjing Medical University, 
    Huai'an 223300,  China; 2. Key Laboratory of Hematology of Nanjing Medical University, 
    Huai'an   223300,  China
  • Online:2019-06-20 Published:2019-06-20
  • Contact: Corresponding author: Wang Chunling, Email:

Abstract: Patients with relapsed/refractory nonHodgkin's lymphoma (R/R NHL) have poor overall prognosis. More and more new drugs and targeted drugs are applied to improve the survival of R/R NHL. Lenalidomide has been used in various subtypes of NHL to improve the therapeutic effect,  especially in Bcell lymphoma,  due to its immunomodulatory effects,  inhibition of angiogenesis and direct antitumor activity. Based on the existing evidence,  this review summarizes the application of lenalidomide to R/R NHL.

Key words: lymphoma, nonHodgkin;lenalidomide;prognosis;drug therapy